Protein Biomarker Shop Peakadilly Closes $10.9M in VC Round | GenomeWeb
NEW YORK (GenomeWeb News) – Protein biomarker company Peakadilly today said it has raised €8.5 million ($10.9 million) in the second and final round of its series A financing.
 
Peakadilly said it will use the cash to increase the capacity of its protein biomarker-discovery operation, which is based on its MASStermind technology.
 
It will also enable it to “accelerate development of its own diagnostic and pharmacodiagnostic products,” the firm said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.